LoriEhrlichMD

PubMed

• 3 citations
  Considerations for Drug Development in Myelodysplastic Syndromes.
  Mikkael A Sekeres, Nina Kim, Amy E DeZern, Kelly J Norsworthy, Jacqueline S Garcia, R Angelo de Claro, Marc R Theoret, Emily Y Jen, Lori A Ehrlich, Amer M Zeidan, Rami...> ;Clinical Cancer Research. 2023 Jul 14
• 2 citations
  Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia.
  Kendra L Sweet, Jorge E Cortes, Jane F Apperley, Mel Mann, Michael J Mauro, Vivian G Oehler, Cristina Ruiz, Charles A Schiffer, Lori A Ehrlich, Gulsum E Pamuk, Joseph ...> ;Clinical Cancer Research. 2023 Jun 13
• 11 citations
  FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes.
  Nina Kim, Kelly J Norsworthy, Sriram Subramaniam, Haiyan Chen, Michael L Manning, Eliford Kitabi, Justin Earp, Lori A Ehrlich, Olanrewaju O Okusanya, Jonathon Vallejo,...> ;Clinical Cancer Research. 2022 Aug 15
• 18 citations
  Accelerating the Global Development of Pediatric Cancer Drugs: A Call to Coordinate the Submissions of Pediatric Investigation Plans and Pediatric Study Plans to the E...
  Gregory H. Reaman, Dominik Karres, Franca Ligas, G. Lesa, Lori A. Ehrlich, Koen Norga, Richard Pazdur> ;Journal of Clinical Oncology. 2020 Sep 18
• 2 citations
  Somatic inactivation of ATM in hematopoietic cells predisposes mice to cyclin D3 dependent T cell acute lymphoblastic leukemia.
  Lori A Ehrlich, Katherine S. Yang-Iott, Amy DeMicco, Craig H. Bassing> ;Cell Cycle. 2015 Feb 6
• 7 citations
  Tcrδ translocations that delete the Bcl11b haploinsufficient tumor suppressor gene promote atm-deficient T cell acute lymphoblastic leukemia
  Lori A Ehrlich, Katherine S. Yang-Iott, Craig H. Bassing> ;Cell Cycle. 2014 Oct 30
• 32 citations
  Pathophysiology of Multiple Myeloma Bone Disease
  Suzanne Lentzsch, Lori A. Ehrlich, G. David Roodman> ;Hematology/oncology Clinics of North America. 2007 Dec 1
• 73 citations
  Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma
  Lanie Francis, Yazan Alsayed, Xavier Leleu, Xiaoying Jia, Ujjal K. Singha, Judith L. Anderson, Michael Timm, Hai Ngo, Ganwei Lu, Alissa Huston, Lori A. Ehrlich, Elizab...> ;Clinical Cancer Research. 2006 Nov 15
• 1 citations
  Eosinophil chemotactic factor-L (ECF-L) enhances osteoclast formation by increasing ICAM-1 expression.
  Veronica Garcia Palacios, Ho Yeon Chung, Sun Jin Choi, Noriyoshi Kurihara, Jun Won Lee, Lori A. Ehrlich, Robert L. Collins, G. David Roodman> ;Annals of the New York Academy of Sciences. 2006 Apr 1
• 69 citations
  The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma
  Lori A. Ehrlich, G. David Roodman> ;Immunological Reviews. 2005 Dec 1
• 139 citations
  IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma
  Lori A. Ehrlich, Ho Yeon Chung, Irene M. Ghobrial, Sun Jin Choi, Francesca Morandi, Simona Colla, Vittorio Rizzoli, G. David Roodman, Nicola Giuliani> ;Blood. 2005 Aug 15
• 106 citations
  MIP-1α utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells
  Yasuo Oba, Jun Won Lee, Lori A. Ehrlich, Ho Yeon Chung, Diane F. Jelinek, Natalie S. Callander, Richard Horuk, Sun Jin Choi, G. David Roodman> ;Experimental Hematology. 2005 Mar 1
• 160 citations
  IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells
  Jun Won Lee, Ho Yeon Chung, Lori A. Ehrlich, Diane F. Jelinek, Natalie S. Callander, G. David Roodman, Sun Jin Choi> ;Blood. 2004 Mar 15
• Join now to see all